Forward Seeks 2nd Fed. Circ. Look At MS Drug Patent Case
Forward Pharma AS has urged the full Federal Circuit to review a panel decision that prevented it from securing royalties from Biogen MA on the multibillion-dollar multiple sclerosis drug Tecfidera, saying...To view the full article, register now.
Already a subscriber? Click here to view full article